Home Clinical Trials Update

Clinical Trials Update

Featured Image: Close-up cityscape of Lugano city waterfront along Lugano Lake. Facades of historic houses in front of alp mountains. Courtesy: © 2017. Fotolia. Used with permission.

15th ICML: Camidanlumab Tesirine Shows High Overall Response Rate in R/R Classical Hodgkin Lymphoma

During the International Conference on Malignant Lymphoma (ICML), one of the must-attend events for the scientific community involved in...

15th ICML: Loncastuximab Tesirine Shows Significant Activity in R/R Diffuse Large B-cell Lymphoma

Loncastuximab tesirine (ADCT‐402), an anti‐CD19 antibody‐drug conjugate (ADC) conjugated via a protease cleavable linker to SG3199, a highly cytotoxic...

Anti-CD205 Antibody-Drug Conjugate MEN1309/OBT076 Shows Substantial in vitro Antitumor Activity

Non-clinical study findings published in the journal Molecular Cancer Therapeutics describing the characterization of the anti-CD205 antibody-drug conjugate (ADC)...
Scientists at work. Courtesy 2019 Fotolia

GTB-1550 Shows Durable Complete Remission in Patients with Chemotherapy-refractory B-cell Malignancies

The investigational anti-cancer agent GTB-1550, also known as OXS-1550 or DT2219 is a novel multi-target directed therapy for the...

EHA 2019: Belantamab Mafodotin in Patients with R/R Multple Myeloma

New, updated, data on belantamab mafodotin, also known as GSK2857916, an investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC),...
General views from the 2019 Annual Meeting of the American Society (ASCO), held May 31 - June 4, 2019. Courtesy © ASCO/Phil McCarten 2019.

RC48-ADC Demonstrates Clinically Meaningful Results in HER2+ Metastatic and Unresectable Urothelial Cancer

Clinically meaningful topline results for a Phase II clinical trial of RC48-ADC were presented during the annual meeting of...
General Views of the 55th Annual Meeting meeting of the American Society of Clinical Oncology. Photo Courtesy: © ASCO/Nick Agro 2019.

Preliminary Phase I Data for U3-1402 Shows Manageable Safety and Reduction in Tumor Size...

Preliminary results from the dose escalation part of the phase I study with U3-1402, an investigational and potential first-in-class...

Depatuxizumab Mafodotin Did Not Demonstrate Survival Benefit in INTELLANCE-1 Study

Depatuxizumab mafodotin (also known as Depatux-M, and previously known as ABT-414), an antibody-drug conjugate (ADC) being developed by AbbVie,...